News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Announces Results Of Tender Offer And Intention To Redeem All Remaining 2006 Notes



10/19/2005 5:13:11 PM

NEW YORK, April 1 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb today announced the results of its cash tender offer to purchase any and all of its outstanding $2.5 billion aggregate principal amount 4.75% Notes due 2006, CUSIP No. 110122 AF 5 (the "Notes"). The offer commenced on Wednesday, March 23, 2005, and expired at 5 p.m., ET, Thursday, March 31, 2005.

The depositary agent, Global Bondholder Services Corporation, has informed the Company that an aggregate principal amount of $1,381,046,000 of the Notes was tendered in the offer.

Bristol-Myers Squibb today also issued a notice of mandatory redemption with respect to all Notes that remain outstanding following consummation of the tender offer. All Notes that remain outstanding following the consummation of the tender offer will be redeemed on Monday, May 2, 2005, at the previously disclosed redemption price of $1,014.06 per $1,000 principal amount.

Bristol-Myers Squibb Company is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Bristol-Myers Squibb

CONTACT: Media: Brian Henry, Communications, +1-609-252-3337, orbrian.henry@bms.com, or Investors: John Elicker, Investor Relations,+1-212-546-3775, or john.elicker@bms.com, both of Bristol-Myers Squibb


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES